- Home
- WDS vs RVMD Comparison
WDS vs RVMD Comparison
Compare WDS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDS | RVMD |
|---|---|---|
| Founded | 1954 | 2014 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9B | 40.3B |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WDS | RVMD |
|---|---|---|
| Price | $23.67 | $176.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 25 |
| Target Price | N/A | ★ $257.80 |
| AVG Volume (30 Days) | 493.2K | ★ 2.2M |
| Earning Date | 08-25-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.45 | N/A |
| Revenue Next Year | $1.63 | $558.43 |
| P/E Ratio | $11.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.38 | $52.48 |
| 52 Week High | $25.19 | $224.31 |
Technical Indicators
Market Signals| Indicator | WDS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.57 | 31.65 |
| Support Level | $22.59 | $93.39 |
| Resistance Level | $24.37 | $194.19 |
| Average True Range (ATR) | 0.32 | 8.85 |
| MACD | 0.20 | -1.91 |
| Stochastic Oscillator | 98.17 | 4.02 |
Price Performance
Historical ComparisonAbout WDS Woodside Energy Group Limited
Incorporated in 1954 and named after the small Victorian town of Woodside, Woodside's early exploration focus moved from Victoria's Gippsland Basin to Western Australia's Carnarvon Basin. First LNG production from the North West Shelf came in 1984. BHP Billiton and Shell each had 40% shareholdings before BHP sold out in 1994 and Shell sold down to 34%. In 2017, Shell sold its entire shareholding. Woodside is one of the most LNG-leveraged companies globally.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.